The drug showed promising results in an international study involving nearly 2,400 participants, and the U.S. Food and Drug ...
New study reveals how lingering spike protein in the brain's borders could explain long-term COVID-19 neurological symptoms and highlight vaccines' protective role. Study: Persistence of spike protein ...
Following a consultation with its emergency task force, the European Medicines Agency (EMA) has backed a drug for adult patients with acute respiratory distress syndrome (ARDS) induced by the SARS‑CoV ...
Live Science on MSN
A pill can stop people from developing COVID after being exposed to the virus, trial finds
A pill called ensitrelvir is the first drug shown to effectively reduce infection after exposure to SARS-CoV-2.
Background Although health problems may persist beyond 4 weeks after SARS-CoV-2 infection, evidence on long-term ophthalmic ...
The “cicada” SARS-CoV-2 variant, which earned its nickname after staying relatively dormant following its discovery in 2024, has accounted for a small proportion of COVID-19 cases since the CDC began ...
USA: Researchers have found in a small case-control study that the virus causing COVID-19 does not persist in placental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results